# Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

> **NCT07379827** · — · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 1500 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Xanomeline and trospium chloride (KarXT)

## Key facts

- **NCT ID:** NCT07379827
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-26
- **Primary completion:** 2028-06-20
- **Final completion:** 2028-06-20
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07379827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07379827, "Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07379827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*